Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Nosopharm Welcomes New Members To Supervisory Board
Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, […]
Nosopharm and GNA NOW Announce Positive Results for the Late Preclinical Development of the First-in-class Antibiotic NOSO-502
Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs […]
Nosopharm Signs Partnership with INRAE and University of Montpellier to Develop New Anti-infectives
Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more